Intelligent Bio Solutions Inc. (INBS)

The immediate outlook is severely bearish as the stock trades at multi-year lows, having lost nearly 99.8% of its value over the last four years. Despite recent headlines celebrating FDA progress and manufacturing partnerships, the market has priced in a catastrophic failure of the business model, evidenced by four consecutive years of negative annual returns and a massive gap between the current price and the analyst mean target. Fundamentally, the company is bleeding cash with negative operating margins, negative free cash flow, and negative returns on equity, while trading below book value. There is no dividend to provide income, and the lack of a multi-year price recovery suggests the market views these operational milestones as insufficient to reverse the structural decline. The short-term technicals remain weak, with the price well below both the 50-day and 200-day moving averages, indicating continued downward pressure despite the optimistic news cycle.